Scopios Opens its Capital Seeking €800,000 to Boost Digital Health

Scopios is opening its doors to strategic partners for the first time. The Madrid-based company, which specializes in digital health, has opened a financing round of $922,700 (€800,000) with which it hopes to develop its new IT system and attract doctors and patients to its platform, according to Raúl Garrido, CEO of Scorpios, and Manuel Macanás, the company’s commercial director.

Macanás and Garrido said that in the round, access preference is given to healthcare professionals, in which “without their support, we will limit our route,” they say. These professionals have access to the minimum ticket for $2,770 (€2,400), compared to other potential investors who have limited access to the ticket of $13,800 (€12,000). The entrepreneurs pointed out that the company’s objective is that the financing round can be closed next December.

The start-up offers a platform that moves the control of healthcare to the healthcare professional and offers health services and medical acts managed entirely and freely by specialists and healthcare centers.

Scopios gives healthcare professionals the opportunity to belong to this new community where they register in a system, without intermediaries, deciding at all times which medical acts and services they freely publish and the way in which they are shown to their potential patients. These users, for their part, must also register in the system.

Read more about Scopios and its plans to raise $922,700 (€800,000) from investors with the Born2Invest mobile app. Our companion app brings you the latest financial news in the world so you can stay on top of the market.

Scopios hopes to reach a network of 1,000 specialists by 2022

The company offers three types of plans, which are adapted to every need. The first is the free plan, under which Scopios allows professionals to publish up to four events at no monthly cost. For its part, the start-up receives a 15% commission for each medical act or service processed from the platform.

The second program is the basic one. This plan allows the professional or medical center to publish up to a maximum of 25 acts or services. In this case, the monthly fee is 39.9 euros plus VAT and a commission of 8% for each act or service processed by Scopios. The last one is the premium plan, with which unlimited acts and services are published for €149.9 plus VAT per month and a commission of 4% for each act or service processed by the platform.

The company was officially launched in 2019, although it has been operating on a fully functional basis since the first half of 2021. Its start-up has meant an investment of 300,000 euros. The company’s goal is that by 2022 it can reach a thousand specialists offering their services or medical acts. For now, there are more than 200 professionals on the platform.

The Madrid-based company intends to make the leap to Portugal next year. In 2022, Scopios will continue to recruit healthcare professionals but will start an intensive campaign for patients. Scopios’ goal for next year is to implement the new IT system with which it intends to start expanding in Portugal.

Consolidation will come in 2023, a year in which the company hopes to have 10% of Spanish healthcare professionals on its platform. In numbers, this means having more than 10,000 healthcare professionals offering its services. By 2024, Scopios aims to have 20% of Spanish healthcare professionals and 10% of Portuguese healthcare professionals. By then, the company aims to grow in countries such as Italy, Germany and the United Kingdom.

By 2025, the company’s goal is to reach 30% of Spanish healthcare professionals and 20% of Portuguese healthcare professionals. Scopios is also exploring the possibility of making the leap to the United States by that year.

__

(Featured image by Pictures of Money CC BY 2.0 via Flickr)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.